Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC by Amanda J.W. Gibson, BSc (Hons), Aliyah Pabani, MD, Michelle L. Dean, BSc, Guillermo Martos, MD, Winson Y. Cheung, MD, MPH, FRCPC, Vishal Navani, M.B.B.S., MRCP, FRACP

Get full text

Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors by Amanda J.W. Gibson, BSc (Hons), Adrian Box, MD, PhD, Michelle L. Dean, BSc, Anifat A. Elegbede, MSc, Desiree Hao, MD, Randeep Sangha, MD, D. Gwyn Bebb, BMBCh, PhD

Get full text

A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada by Anifat A. Elegbede, MSc, MbChB, Amanda J. Gibson, BSc, Andrea S. Fung, PhD, MD, Winson Y. Cheung, MD, MPH, Michelle L. Dean, BSc, D. Gwyn Bebb, BMBCh, PhD, Aliyah Pabani, MD

Get full text

Expected Cost Savings From Low-Dose Computed Tomography Scan Screening for Lung Cancer in Alberta, Canada by Nguyen Xuan Thanh, MD, PhD, Truong-Minh Pham, MD, PhD, Arianna Waye, PhD, Alain Tremblay, MDCM, Huiming Yang, MD, Michelle L. Dean, BSc, Tracy Wasylak, MSc, Randeep Sangha, MD, Douglas Stewart, MD

Get full text